BIOC

Biocept, Inc. [BIOC] Stock Forecast

Q: What is Biocept, Inc. stock symbol ?

Biocept, Inc. is a US stock, located in San diego of Ca and trading under the symbol BIOC

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BIOC Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Has a high level of debt. Debt-to-Equity ratio of 39.97 is considered high.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 26.27%

Earnings are expected to fall -100% next year

Does not have any significance market cap ($1.14M)

BIOC has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

BIOC Financial details

Company Rating

Buy

Market Cap

1.14M

Income

-34.9M

Revenue

-3.44M

Book val./share

0.28

Cash/share

6.4

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

20 Nov 2023

P/E

-0.01

Forward P/E

PEG

-0

P/S

-0.33

P/B

1.55

P/C

0.07

P/FCF

-0.06

Quick Ratio

1.52

Current Ratio

1.81

Debt / Equity

39.97

LT Debt / Equity

33.4

EPS (TTM)

-58.12

EPS next Y

EPS next Q

EPS this Y

890.92%

EPS next Y

EPS next 5Y

EPS last 5Y

-53.58%

Revenue last 5Y

51.4%

Revenue Q/Q

-12.48%

EPS Q/Q

-71.59%

SMA20

SMA50

SMA100

Inst Own

107.76%

Inst Trans

2.78%

ROA

-158%

ROE

-357%

ROC

-2.17%

Gross Margin

556%

Oper. Margin

1088%

Profit Margin

1016%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.32-27.0

52W High

52W Low

RSI

Rel Volume

0.31

Avg Volume

2.16M

Volume

671.57K

Perf Week

97.68%

Perf Month

Perf Quarter

Perf Half Y

-20.46%

Beta

0.595

Volatility

0.13%, 0.17%

Prev Close

720.57%

Price

0.4349

Change

624.83%

BIOC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	348.48	80.28	69.55	124.36	45.76
Net income per share	-2.63K	-357.41	-43.16	-5.73	-56.78
Operating cash flow per share	-2.4K	-334.68	-50.11	7.49	-23.52
Free cash flow per share	-2.41K	-345.36	-52.31	4.3	-24.94
Cash per share	367.04	135.06	36.39	58.6	22.82
Book value per share	326.21	162.64	60	76.1	15.68
Tangible book value per share	326.21	162.64	60	76.1	15.68
Share holders equity per share	326.21	162.64	60	76.1	15.68
Interest debt per share	207.73	67.1	36.89	26.32	21.99
Market cap	2.41M	5.99M	52.59M	53.49M	8.99M
Enterprise value	609.54K	-769.83K	50.45M	37.3M	8.2M
P/E ratio	-0.1	-0.24	-3.09	-18.94	-0.28
Price to sales ratio	0.74	1.08	1.92	0.87	0.35
POCF ratio	-0.11	-0.26	-2.66	14.5	-0.68
PFCF ratio	-0.11	-0.25	-2.55	25.25	-0.64
P/B Ratio	0.79	0.53	2.22	1.43	1.01
PTB ratio	0.79	0.53	2.22	1.43	1.01
EV to sales	0.19	-0.14	1.84	0.61	0.32
Enterprise value over EBITDA	-0.03	0.03	-3.26	-15.48	-0.26
EV to operating cash flow	-0.03	0.03	-2.55	10.11	-0.62
EV to free cash flow	-0.03	0.03	-2.44	17.61	-0.58
Earnings yield	-10.21	-4.11	-0.32	-0.05	-3.57
Free cash flow yield	-9.35	-3.97	-0.39	0.04	-1.57
Debt to equity	0.53	0.23	0.52	0.34	1.37
Debt to assets	0.19	0.14	0.26	0.21	0.39
Net debt to EBITDA	0.07	0.29	0.14	6.72	0.02
Current ratio	1.3	2.5	2.61	3.88	2.97
Interest coverage	-78.01	-11.08	-6.61	-8.31	-101.21
Income quality	0.91	0.92	1.11	-1.31	0.41
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.18	1.26	0.36	0.21	0.62
Research and developement to revenue	1.37	0.85	0.19	0.08	0.24
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.03	0.04	-0.43	0.06
Capex to revenue	-0.04	-0.13	-0.03	-0.03	-0.03
Capex to depreciation	-0.18	-0.95	-0.87	-0.6	-0.49
Stock based compensation to revenue	0.19	0.16	0.03	0.04	0.12
Graham number	4.4K	1.14K	241.4	99.08	141.52
ROIC	-3.85	-1.39	-0.31	-0.04	-0.97
Return on tangible assets	-2.81	-1.39	-0.36	-0.05	-1.04
Graham Net	-86.85	84.2	5.53	35.72	-12.61
Working capital	1.4M	8.33M	20.1M	33.92M	10.84M
Tangible asset value	3.04M	11.2M	23.69M	37.48M	8.86M
Net current asset value	303.1K	7.36M	8.83M	22.76M	-5.67M
Invested capital	0.53	0.23	0.52	0.34	1.37
Average receivables	1.38M	2.55M	8.84M	13.97M	7.97M
Average payables	1.65M	2.03M	5.19M	7.81M	4.38M
Average inventory	542.96K	677.6K	1.35M	2.29M	1.7M
Days sales outstanding	176.79	232.86	188.01	82.15	30.36
Days payables outstanding	74.07	66.89	143.09	70.03	19.55
Days of inventory on hand	21.32	25.54	33.01	25.62	9.72
Receivables turnover	2.06	1.57	1.94	4.44	12.02
Payables turnover	4.93	5.46	2.55	5.21	18.67
Inventory turnover	17.12	14.29	11.06	14.25	37.57
ROE	-8.08	-2.2	-0.72	-0.08	-3.62
Capex per share	-15.57	-10.68	-2.2	-3.19	-1.43

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	18.83	9.86	-18.08	1.15	0.57
Net income per share	-9.59	-9.73	-32.57	-12.32	-3.5
Operating cash flow per share	-7.17	-7.19	-7.46	-10.55	-2.98
Free cash flow per share	-7.55	-7.82	-7.7	-10.7	-3.07
Cash per share	40.69	31.81	22.68	11.53	6.4
Book value per share	57.59	48.57	15.58	4.13	0.28
Tangible book value per share	57.59	48.57	15.58	4.13	0.28
Share holders equity per share	57.59	48.57	15.58	4.13	0.28
Interest debt per share	22.39	21.73	21.37	19.8	11.23
Market cap	15.89M	15.64M	9.04M	5.99M	1.25M
Enterprise value	5.43M	9.88M	8.26M	10.8M	6.21M
P/E ratio	-0.73	-0.71	-0.12	-0.21	-0.09
Price to sales ratio	1.5	2.8	-0.88	8.9	2.13
POCF ratio	-3.93	-3.84	-2.13	-0.97	-0.41
PFCF ratio	-3.73	-3.53	-2.07	-0.95	-0.39
P/B Ratio	0.49	0.57	1.02	2.47	4.32
PTB ratio	0.49	0.57	1.02	2.47	4.32
EV to sales	0.51	1.77	-0.8	16.05	10.55
Enterprise value over EBITDA	-1.07	-1.94	-0.45	-1.67	-1.1
EV to operating cash flow	-1.34	-2.42	-1.95	-1.74	-2.01
EV to free cash flow	-1.28	-2.23	-1.89	-1.72	-1.95
Earnings yield	-0.34	-0.35	-2.05	-1.21	-2.9
Free cash flow yield	-0.27	-0.28	-0.48	-1.05	-2.54
Debt to equity	0.38	0.45	1.37	4.77	39.97
Debt to assets	0.21	0.24	0.39	0.5	0.52
Net debt to EBITDA	2.05	1.13	0.04	-0.74	-0.88
Current ratio	4.55	5.13	2.97	2.07	1.81
Interest coverage	-32.88	-107.25	-395.81	-154.3	-122.28
Income quality	0.77	0.74	0.23	0.87	0.85
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.41	0.55	-0.19	4.44	5.93
Research and developement to revenue	0.16	0.24	-0.12	1.55	0.69
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	0.09	0.03	0.01	0.03
Capex to revenue	-0.02	-0.06	0.01	-0.14	-0.16
Capex to depreciation	24.11	-0.87	-0.31	-0.15	-0.26
Stock based compensation to revenue	0.06	0.08	0.01	0.47	0.35
Graham number	111.51	103.11	106.84	33.85	4.7
ROIC	-0.09	-0.11	-0.56	-0.28	-0.28
Return on tangible assets	-0.09	-0.11	-0.6	-0.31	-0.16
Graham Net	20.23	12.73	-12.53	-21.46	-13.8
Working capital	34.17M	29.49M	10.84M	4.7M	3.96M
Tangible asset value	32.46M	27.52M	8.86M	2.43M	290K
Net current asset value	18.09M	13.05M	-5.67M	-11.48M	-12.95M
Invested capital	0.38	0.45	1.37	4.77	39.97
Average receivables	16.86M	16.57M	8.96M	1.63M	956K
Average payables	6.45M	3.94M	2.28M	1.53M	1.5M
Average inventory	2.74M	2.07M	1.33M	730.5K	627.5K
Days sales outstanding	147.38	254	-18.82	148.71	122.24
Days payables outstanding	54.18	47.37	31.82	45.56	51.78
Days of inventory on hand	25.23	29.56	15.82	20.92	19.45
Receivables turnover	0.61	0.35	-4.78	0.61	0.74
Payables turnover	1.66	1.9	2.83	1.98	1.74
Inventory turnover	3.57	3.04	5.69	4.3	4.63
ROE	-0.17	-0.2	-2.09	-2.98	-12.52
Capex per share	-0.39	-0.63	-0.24	-0.15	-0.09

BIOC Frequently Asked Questions

What is Biocept, Inc. stock symbol ?

Biocept, Inc. is a US stock , located in San diego of Ca and trading under the symbol BIOC

What is Biocept, Inc. stock quote today ?

Biocept, Inc. stock price is $0.4349 today.

Is Biocept, Inc. stock public?

Yes, Biocept, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 2.16M
Market Capitalization 1.14M
Employee 50
CEO Mr. Darrell Taylor Esq.
Headquarters San Diego,CA,US
IPO Date 2014-02-05
Website https://biocept.com

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.